Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hemophagocytic lymphohistiocytosis due to infections, autoimmune disorders, or underlying malignancies. Signs and symptoms include fever, lymphadenopathy, hepatomegaly, splenomegaly, and pancytopenia.
Biomarker and diagnostic research for secondary hemophagocytic lymphohistiocytosis has been reported in the published literature.
3 clinical trials registered, 3 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE4, 1 PHASE2. Research is sponsored by a mix of industry and academic institutions.
141 publications have been identified in PubMed for secondary hemophagocytic lymphohistiocytosis. Research spans Case Report / Case Series (53%), Review / Meta-Analysis (14%), and Epidemiology / Natural History (12%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 75 |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 1:42 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries | 20 | 14% |
Disease patterns and progression | 17 | 12% |
Testing and diagnosis research | 13 | 9% |
Laboratory research | 6 | 4% |
Other research | 5 | 4% |
Clinical study results | 3 | 2% |
New treatment approaches | 2 | 1% |
Hu Y (2026). [PMID: 41996460](https://pubmed.ncbi.nlm.nih.gov/41996460/). *PLoS Negl Trop Dis*. [Diagnostic / Biomarker]
Keramane HZ (2026). [PMID: 42064515](https://pubmed.ncbi.nlm.nih.gov/42064515/). *Cureus*. [Case Report / Case Series]
Chowdhary S (2026). [PMID: 41284220](https://pubmed.ncbi.nlm.nih.gov/41284220/). *Indian Pediatr*. [Case Report / Case Series]
Wang X (2026). [PMID: 41708804](https://pubmed.ncbi.nlm.nih.gov/41708804/). *Ann Hematol*. [Case Report / Case Series]
Cevizli D (2026). [PMID: 41979714](https://pubmed.ncbi.nlm.nih.gov/41979714/). *Pediatr Nephrol*. [Clinical Trial Publication]
Cavdar VC (2026). [PMID: 42037832](https://pubmed.ncbi.nlm.nih.gov/42037832/). *Cureus*. [Case Report / Case Series]
Khongwichit S (2026). [PMID: 42061499](https://pubmed.ncbi.nlm.nih.gov/42061499/). *Int J Infect Dis*. [Case Report / Case Series]
Odum JD (2026). [PMID: 42160475](https://pubmed.ncbi.nlm.nih.gov/42160475/). *Am J Physiol Renal Physiol*. [Basic Science / Preclinical]
Ling X (2026). [PMID: 41482007](https://pubmed.ncbi.nlm.nih.gov/41482007/). *Exp Hematol*. [Other]
Kant S (2026). [PMID: 41640894](https://pubmed.ncbi.nlm.nih.gov/41640894/). *Cureus*. [Case Report / Case Series]
AI-curated news mentioning secondary hemophagocytic lymphohistiocytosis
Updated May 27, 2026
A recent case report details a pediatric patient with AQP4+ neuromyelitis optica spectrum disorder (NMOSD), MDA5+ clinically amyopathic dermatomyositis, and secondary hemophagocytic lymphohistiocytosis (sHLH). This study contributes to the understanding of these rare conditions and their clinical presentations.